Your browser doesn't support javascript.
loading
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti, Sylvie; Hamy, Anne-Sophie; Delaloge, Suzette; Brain, Etienne; Berger, Frédérique; Sigal-Zafrani, Brigitte; Mathieu, Marie-Christine; Bertheau, Philippe; Guinebretière, Jean Marc; Saghatchian, Mahasti; Lerebours, Florence; Mazouni, Chafouny; Tembo, Olivier; Espié, Marc; Reyal, Fabien; Marty, Michel; Asselain, Bernard; Pierga, Jean-Yves.
Afiliação
  • Giacchetti S; AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, 75475 Paris, France. Electronic address: sylvie.giacchetti@aphp.fr.
  • Hamy AS; Institut Curie, PSL Research University, Translational Research Department, INSERM, U932 Immunity and Cancer, Residual Tumor & Response to Treatment Laboratory (RT2Lab), Paris, France.
  • Delaloge S; Medical Oncology Department, Gustave Roussy, Cancer Center Villejuif, France.
  • Brain E; Medical Oncology Department, Institut Curie, Saint Cloud, Paris, France.
  • Berger F; Biostatistics Department, Institut Curie, Paris, France.
  • Sigal-Zafrani B; Tumor Biology Department, Institut Curie, Saint Cloud, Paris, France.
  • Mathieu MC; Pathology Department, Gustave Roussy, Cancer Center Villejuif, France.
  • Bertheau P; AP-HP, Hôpital Saint-Louis, Pathology Department, University Paris Diderot, Paris, France.
  • Guinebretière JM; Tumor Biology Department, Institut Curie, Saint Cloud, Paris, France.
  • Saghatchian M; Medical Oncology Department, Gustave Roussy, Cancer Center Villejuif, France.
  • Lerebours F; Medical Oncology Department, Institut Curie, Saint Cloud, Paris, France.
  • Mazouni C; Department of Surgery, Gustave Roussy, Cancer Center Villejuif, France.
  • Tembo O; Center for Therapeutic Innovations in Oncology and Haematology (CITOH), APHP, Hôpital Saint-Louis, Paris, France.
  • Espié M; AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, 75475 Paris, France.
  • Reyal F; Institut Curie, PSL Research University, Translational Research Department, INSERM, U932 Immunity and Cancer, Residual Tumor & Response to Treatment Laboratory (RT2Lab), Paris, France; Department of Surgery, Institut Curie, Paris, France.
  • Marty M; AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, 75475 Paris, France; Center for Therapeutic Innovations in Oncology and Haematology (CITOH), APHP, Hôpital Saint-Louis, Paris, France.
  • Asselain B; UMR 8081 'IR4M', Université Paris-Sud, 91400 Orsay, France.
  • Pierga JY; Medical Oncology Department, Institut Curie, Saint Cloud, Paris, France; Université Paris Descartes, Sorbonne Paris Cite, Paris, France.
Eur J Cancer ; 75: 323-332, 2017 04.
Article em En | MEDLINE | ID: mdl-28279941
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido